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Matin M. Imanguli,1 Jane C. Atkinson,2
Sandra A. Mitchell,3 Daniele N. Avila,1 Rachel J. Bishop,4
Edward W. Cowen,5 Manuel B. Datiles,4 Frances T. Hakim,1
David E. Kleiner,6 Michael C. Krumlauf,1 Steven Z. Pavletic1Although xerostomia is a commonly reported complaint in patients with chronic graft-versus-host disease
(cGVHD), criteria for evaluating the prevalence and characteristics of salivary gland involvement have not
been well defined in this patient population. Previous studies also have made no distinction between salivary
andmucosal oral cGVHD.We systematically evaluated signs and symptoms of sicca in a large cohort of patients
with cGVHD (n5 101) using instruments widely used to study Sjogren’s syndrome. Xerostomiawas reported
by 77% of the patients and was associated with xerophthalmia in all but 1 case. The salivary flow rate was#0.2
mL/min in 27%, and#0.1mL/min in 16%.Histopathological changes, consisting ofmononuclear infiltration and/
or fibrosis/atrophy, were present in all patients with salivary dysfunction. Importantly, therewas no correlation
of salivary and oral mucosal involvement in cGVHD. Patients with cGVHD-associated salivary gland involve-
ment had diminished oral cavity-specific quality of life and lower body mass index. Salivary gland involvement
is a common and clinically distinct manifestation of cGVHD. Formal evaluation of salivary function using stan-
dardized criteria is needed, and this could be incorporated as an outcomemeasure in clinical trials of cGVHD.
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Chronic graft-versus-host disease (cGVHD) is the
single most important complication in long-term
survivors after allogeneic hematopoietic stem cell
transplantation (allo-HSCT) [1]. Involvement of
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ing hyposecretion of saliva and tears.
Xerostomia can be a distressing symptom, and de-
creased salivary flow may lead to reduced food intake,
dental caries, and oral mucosal infection with Candida
species [2]. In addition, salivary dysfunction may be
associated with other, more severe manifestations of
cGVHD, such as pulmonary involvement [3]. There-
fore, formal assessment of salivary gland dysfunction
is important in an overall assessment of cGVHD. Sali-
vary gland function can be assessed using noninvasive
tests, and could be used as an outcome in clinical trials.
Whereas the prevalence of xerophthalmia after allo-
HSCT has been estimated to range between 40% and
70% in various studies [4-6], the prevalence of salivary
gland involvement has not been well described [7].
Oral dryness complaints in cGVHD are often reported
as ‘‘oral’’ or ‘‘mouth’’ involvement, and are not distin-
guished from oral mucosal lesions [8]. This is in part be-
cause older literature implied that the pathologic
changes of the minor salivary glands found in cGVHD
represented a continuum of the oral mucosal lesions
found in the disease. However, oral mucosal and salivary
gland involvement in cGVHD bear close resemblance
Table 1. Patient Characteristics (n 5 101)
Diagnosis, n (%)
Acute leukemia/myelodysplastic syndrome 42 (41)
Chronic leukemia 23 (23)
Lymphoma 21 (21)
Multiple myeloma 8 (8)
Aplastic anemia/myelofibrosis 5 (5)
Paroxysmal nocturnal hemoglobinuria 2 (2)
Conditioning, n (%)
Myeloablative 59 (59)
Reduced intensity 42 (41)
Donor type, n (%)
Matched sibling donor 73 (72)
Matched unrelated donor 28 (28)
Stem cell source, n (%)
Bone marrow 19 (19)
Peripheral blood 80 (79)
Unknown 2 (2)
Karnofsky Performance Status score, mean (SD), range 81 (12), 30-100
Months since transplantation, mean (SD), range 43 (38), 4-201
Months since cGVHD diagnosis, mean (SD), range 36 (37), 1-196
cGVHD indicates chronic graft-versus-host disease.
Table 2. Characteristics of Patients with cGVHD (n 5 101)
Salivary Dysfunction
Present
(n 5 22)
Absent
(n 5 59)
Onset of cGVHD, n (%)
De novo 10 (45) 21 (36)
Quiescent 2 (9) 13 (22)
Progressive 10 (45) 25 (42)
Platelet count #100,000, n (%) 5 (23) 4 (7)
Clinician global rating of
cGVHD, n (%)
Mild 0 (0) 2 (3)
Moderate 8 (36) 24 (41)
Severe 11 (50) 26 (44)
Missing 3 (14) 7 (12)
Change in cGVHD over previous
month, n (%)
Better 5 (23) 10 (17)
About the same 9 (41) 18 (31)
Worse 8 (36) 31 (53)
Intensity of current
immunosuppression, n (%)
None 3 (14) 5 (8)
Mild* 2 (9) 6 (10)
Moderate† 9 (41) 16 (27)
High‡ 8 (36) 22 (59)
Chronic GVHD clinical severity
score, mean (SD), range
37 (10), 19-56 30 (9), 7-48
Lee cGVHD symptom scale
total score, mean (SD), range
34 (14), 11-69 25 (13), 1-60
cGVHD indicates chronic graft-versus-host disease.
*Single agent prednisone <0.5 mg/kg/day.
†Single agent prednisone $0.5 mg/kg/day or single agent/modality with
and without prednisone $0.5 mg/kg/day.
‡Two or more agents/modalities with and without prednisone$0.5 mg/
kg/day.
Biol Blood Marrow Transplant 16:1362-1369, 2010 1363Salivary Gland Disease in cGVHDto autoimmune disorders affecting these tissues, specif-
ically oral lichen planus and SS, which occur indepen-
dently of each other and affect distinct patient
populations. Although guidelines for evaluation of lacri-
mal dysfunction in cGVHD were defined in the recent
National Institutes of Health (NIH) consensus criteria
[9,10], no recommendations have been provided for
evaluation of salivary gland involvement. Therefore,
the aim of this study was to systematically examine
the characteristics and correlates of salivary gland
function in cGVHD and to determine whether oral
mucosal and salivary gland pathology in cGVHD
occurred independently. We also developed preliminary
guidelines that could be used to evaluate patients with
cGVHD who report oral dryness.PATIENTS AND METHODS
Patients
A total of 101 consecutive adult patients enrolled in
a cGVHD cross-sectional study (clinicaltrials.gov
#NCT00331968) were included in this study. The
study was approved by the National Cancer Institute’s
Institutional Review Board, and informed consent was
obtained from all participants. Patients underwent
comprehensive multispecialty clinical evaluation, lab-
oratory testing, and research sample collection, and
they completed a series of patient-reported outcome
measures. The diagnosis of cGVHD was established
using NIH consensus criteria [9]. The sample had
a mean patient age of 45.9 6 12 years (range, 20-66
years), predominantly white (n 5 92; 91%), and with
approximately equal representation of males (n 5 53;
52%) and females (n 5 48; 48%). The median time
from transplantation to cGVHD diagnosis was 5
months (range, 3-35 months). Most patients had active
moderate or severe cGVHD requiring continuation ofsystemic immunosuppression. Transplant and
cGVHD characteristics for the sample are presented
in Tables 1–3.
Clinical Evaluations
Salivary and lacrimal symptoms were evaluated us-
ing methods described by the American-European
Consensus Group (AECG) for SS [11]. The presence
of xerostomia and xerophthalmia were determined us-
ing the 3-item AECG screening questionnaire, which
assesses both the presence and duration of symptoms.
Patient-reported symptoms of dry mouth have been
reported to not correlate well with objective measures
of salivary function [12]. In addition, xerostomia sever-
ity was graded on a patient-reported scale of 0-10.
Evaluation of salivary gland function was per-
formed by measuring the unstimulated salivary flow
rate using 5-minute saliva collection into a preweighed
50-ml centrifuge tube in a modification of a procedure
described previously [13]. Objective evaluation of lac-
rimal function included Schirmer’s test (performed
with local anesthesia) and evaluation of keratopathy
and conjunctival involvement by fluorescein and liss-
amine green staining according to European-U.S. cri-
teria for evaluation of SS [11]. A Schirmer’s test score
of #5 mm in 5 minutes was considered abnormal.
Table 3. Prevalence of cGVHD Organ System Involvement
Based on NIH Scoring
Salivary Dysfunction
Organ System Involved, n (%) Present (n 5 19) Absent (n 5 52)
Skin 13 (68) 41 (79)
Oral cavity (any manifestation) 18 (95) 37 (71)
Eyes 18 (95) 40 (77)
Lungs 10 (53) 26 (51)
Liver 9 (47) 25 (48)
GI tract 11 (58) 17 (33)
Joints/fascia 8 (42) 29 (56)
Genital tract (women only) 7 (50) 13 (41)
Total number of organ systems
involved, median (range)
4.5 (3-7) 4.0 (2-8)
cGVHD indicates chronic graft-versus-host disease.
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developed for scoring oral mucositis lesions and oral
lichen planus, a condition clinically very similar to
oral cGVHD [14].
Oral cavity-specific quality of life (ie, the impact of
an oral health condition on talking, eating, self-esteem,
mood, and role function) was assessed with the 14-item
Oral Health Impact Profile (OHIP-14) questionnaire,
which has been validated in various oral conditions
[15]. Health-related quality of life (HRQL) was
assessed using the Functional Assessment of Cancer
Therapy (FACT-G) questionnaire [16], and selected
aspects of cGVHD were evaluated on the Lee cGVHD
symptom scale [17]. Overall and organ-specific
cGVHD severity was assessed based on detailed multi-
disciplinary clinical and diagnostic evaluation of the
skin, mouth, eyes, liver, lungs, gastrointestinal (GI)
system, functional capacity, and gynecologic manifes-
tations in women. Scoring of individual organ systems
was based on the NIH criteria for diagnosis and stag-
ing [9]. Using objective criteria, organ system subspe-
cialists graded the severity of cGVHD in each of 8
organ systems, and a summed severity score ranging
from 0-100 was calculated.Histopathology
Minor salivary glands (MSGs) were collected from
the lower lip of consenting patients using a standard
procedure [18], fixed in formalin, and embedded in
paraffin. Hemtoxylin and eosin-stained sections were
evaluated by a pathologist with expertise in cGVHD
and SS who was blinded to clinical evaluation data.
The degree of mononuclear infiltration was deter-
mined based on focus score (number of lymphocytic
foci of$50 cells per 1 mm2 of the minor salivary gland
section) and Greenspan grade (0-4 scoring of the infil-
trate density) [19]. Glandular atrophy and fibrosis were
scored separately on a scale of 0-3, based on the pro-
portion, by thirds, of glandular parenchyma affected.
The presence or absence of perilobular fibrosis, duct
rupture, and ductitis was recorded as well.Statistical Methods
Thec2 test or Fisher’s exact test was used to evaluate
differences in proportions as appropriate. Group differ-
ences were assessed using Wilcoxon’s rank-sum test for
continuous variables and the exact Cochran-Armitage
test for ordered and categorical variables. Analysis of
covariance was used to identify the strength of the asso-
ciation between outcomes of interest while controlling
for the effects of other parameters that might have an
impact on the findings. Correlations between 2 contin-
uously measured parameters were determined using
Spearman’s rank correlation coefficient, r, with the
strength of the association between parameters
interpreted as follows: jrj .0.70, strong correlation;
0.50\jrj\0.70, moderately strong correlation; 0.30\
jrj \ 0.50, weak to moderately strong correlation;
and jrj\0.30, weak correlation.
All P values are 2-tailed and are presented without
formal adjustment for multiple comparisons. How-
ever, in view of the exploratory nature of the study,
the varying degrees of independence among the tests,
and the number of tests performed, a P value\.005
might be considered a statistically significant result,
whereas a result for which .005\ P\.05 would be
considered a strong trend. All calculations were per-
formed using MedCalc version 9.3.0.0 (Mariakerke,
Belgium) and SPSS for Windows version 15.0 (SPSS
Inc, Chicago, IL).RESULTS
Prevalence of Salivary and Lacrimal Dysfunction
in cGVHD Patients
A summary of clinical parameters is presented in
Supplemental Table 1. Seventy-eight patients (77%)
completed the 6-item SS questionnaire. Overall, 66
patients (86%) gave at least one positive answer on
the questionnaire, with 60 (77%) reporting oral
complaints and 51 (67%) reporting ocular complaints.
There was a significant association between symptoms
of ocular and oral dryness, with 46 patients (59%)
reporting both complaints (P 5 .0017; c2 for number
of patients with ocular or oral complaints).
We then evaluated lacrimal and salivary function
using clinician-assessed measures. Based on the NIH
consensus criteria on cGVHD diagnosis and staging
[9,10], we considered an abnormal Schirmer tear test
and/or the presence of keratopathy in at least one eye
to indicate decreased lacrimal function. Decreased
salivary gland function was defined as an
unstimulated salivary flow rate of \1 mL in 5
minutes (0.2 mL/min), a value consistent with the
lower limit of normal salivary function determined
by population studies [20].
Using these criteria, salivary dysfunction was less
prevalent than lacrimal dysfunction in our cGVHD
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of the 98 patients for whom results were available
had a Schirmer tear test score of #5 mm (73%). Ker-
atopathy as established by positive corneal staining,
was seen in 57 of these patients (58%). As expected,
the severity of keratopathy was correlated with
Schirmer tear test values (r 5 20.52; P \.001). All
but one patient with salivary dysfunction had lacrimal
dysfunction as well.
We also examined the correlation of objective
measures of salivary and lacrimal flow and patients’
symptoms. There was a moderately good correlation
between self-reported xerostomia and salivary flow
rate (r 5 20.51; P\.001). A similar correlation was
found between patient-reported ocular dryness and
Schirmer test results (r 5 20.55 for the left eye and
20.52 for the right eye; P\.001).
An easily administered screening test would be
useful to guide subsequent evaluation of lacrimal and
salivary gland function in cGVHD. Consequently,
we evaluated the predictive ability of the SS question-
naire (SSQ) with regard to decreased salivary and/or
lacrimal function on clinical testing. Seventy-six
patients had both patient-reported and clinician-
assessed evaluations of salivary and lacrimal function.
Fifty-four out of 64 patients with lacrimal dysfunction
and 5 out of 12 patients with a normal eye exam
endorsed at least 1 of the 3 ocular items on the SSQ
(sensitivity, 84%; specificity, 58%; positive predictive
value [PPV], 92%; negative predictive value, [NPV]
41%). Of 21 patients with a low salivary flow rate, 19
responded positively to at least one item on SSQ.
Among 55 patients with clinically normal salivary
flow rates, 23 had a negative questionnaire (sensitivity,
90%; specificity, 42%; PPV, 37%; NPV, 92%). These
data suggest that the eye component of the SSQ might
be most useful to rule in patients likely to have positive
findings on the ophthalmologic exam, whereas the oral
component would be most useful for ruling out signif-
icant salivary flow reduction. The predictive values re-
ported here should be interpreted with caution,
however, given that the prevalence of lacrimal and
salivary gland dysfunction in our study might be
higher than that in the general cGVHD/allo-HSCT
population.Lack of Association between Salivary Gland
Dysfunction and Oral Mucosal Disease
To explore the hypothesis that salivary gland and
mucosal involvement represent distinct manifestations
of cGVHD, we evaluated the covariation between the
presence and severity of mucosal involvement and
salivary gland dysfunction in our cohort. Of 75
patients for whom both data points were available for
analysis, only 14 had both salivary gland dysfunction
and oral mucosal involvement. Forty-one patientshad only mucosal dysfunction, and 5 had only salivary
gland dysfunction. Fifteen patients had neither muco-
sal involvement nor salivary dysfunction (P 5 1.0,
Fisher’s exact test for proportions of patients with mu-
cosal and/or salivary involvement). There was no
correlation between the degree of mucosal changes
as measured by specific grading scale and salivary
flow rate (r 5 0.09; P 5 .42). Similarly, there was no
difference in cGVHD oral mucosal severity scores
between patients with (median, 4.5; 25th-75th percen-
tile, 0.25-6.0; n 5 19) and without salivary gland
dysfunction (median, 3.5; 25th-75th percentile,
0-9.8; n 5 56; P 5 0.93) or in salivary flow rates
between patients with (median, 0.36 mL/min;
25th-75th percentile, 0.20-0.67 mL/min; n 5 55)
and without mucosal disease (median, 0.35 mL/min;
25th-75th percentile, 0.20-0.59 mL/min; n 5 20;
P 5 .59). These findings suggest that salivary and
oral mucosal involvement in cGVHD are distinct dis-
ease manifestations and not extensions of one another.Salivary Gland Dysfunction Is Associated with
ImpairedOral Cavity-SpecificQuality of Life and
Decreased Body Mass Index
We used a validated oral cavity-specific quality-of-
life questionnaire (OHIP-14) to evaluate the impact of
salivary gland dysfunction on the oral quality of life of
patients with cGVHD. OHIP-14 scores were signifi-
cantly higher (indicating greater impairment in quality
of life) in patients with salivary gland dysfunction
(median, 12; 25th-75th percentile, 10-29; n 5 21 vs
median, 6.5, 25th-75th percentile, 1-13; n 5 54;
P\.001). Greater impairment in oral cavity-specific
quality of life also was associated with more perceived
oral dryness (r5 0.49; P\.001) and lower salivary flow
rate (r 5 20.41; P\.001). Surprisingly, we found no
statistically significant difference in OHIP-14 score
between patients with and those without oral mucosal
cGVHD (median, 10; 25th-75th percentile, 3-17;
n 5 51 vs median, 6.5, 25th-75th percentile, 1-10;
n 5 20; P 5 .19). Furthermore, although quality-of-
life scores correlated well with the degree of oral
discomfort (r 5 0.43; P\.001), they were not associ-
ated with the clinician-assessed severity of oral muco-
sal disease (r 5 0.21; P 5 .09). Although other oral
conditions, such as caries or periodontal disease, could
have had an impact on oral quality-of-life scores, such
changes were not often seen in our patient cohort.
There was no statistically significant relationship
between the presence of salivary gland dysfunction
and overall HRQL as assessed by FACT-G, a global
HRQL scale, controlling for age and cGVHD severity
(P 5 .193). Salivary dysfunction can result in impaired
nutritional status, however. Patients with salivary gland
dysfunction reported significantly greater difficulty in
swallowing solid foods (P5 .001) on the Lee cGVHD
1366 Biol Blood Marrow Transplant 16:1362-1369, 2010M. M. Imanguli et al.symptom scale. After adjusting for cGVHD severity,
patients with salivary involvement also had significantly
(P5 .008) lower body mass index (BMI) than those with
an intact salivary flow rate (estimated marginal mean
BMI, 21.9; 95% CI, 19.6-24.2; n 5 22 vs 25.3; 95%
CI, 24.1-26.6; n 5 59). These differences in BMI
remained when we adjusted specifically for the severity
of cGVHD GI manifestations (P5 .001). There was no
difference in BMI between groups with and without GI
symptoms (mean BMI, 24.2; 95% CI, 20.8-27.6; n5 19
vs 25.1; 95% CI, 24.0-26.2; n5 79; P5.51).Histopathological Changes in Patients with
Salivary Gland Dysfunction
MSG tissue specimens were available from 36
patients. Six patients did not have complete clinical in-
formation and thus were excluded from analysis. Gross
examination commonly revealed such features as peri-
ductal infiltration (Figure 1A), atrophy of salivary
gland lobules, and periglandular fibrosis (Figure 1B).
In some patients, atrophy was so severe that no MSG
tissue could be identified.
Patients with clinically observed salivary gland
dysfunction had higher atrophy (median, 2; 25th-
75th percentile, 0.5-3.0; n 5 8 vs 0.5; 25th-75th per-
centile, 0-2.0; n 5 22; P 5 .16), fibrosis (median, 2;
25th-75th percentile, 0.5-3.0; n 5 8 vs 0; 25th-75th
percentile, 0-2.0; n 5 22; P 5 .12), and focus scores
(median, 0.50; 25th-75th percentile, 0-2.5; n 5 8 vs
0; 25th-75th percentile, 0-1.0; n 5 22), although the
differences did not reach statistical significance. There
was a difference in Greenspan grade (median, 2.5;
25th-75th percentile, 2.0-4.0; n 5 8 vs 2; 25th-75th
percentile, 1.0-3.0; n5 22; P5 .04). The group of pa-
tients with a Greenspan grade .1 had lower salivary
flow rates (median, 0.24 mL/min; 25th-75th percen-
tile, 0.16-0.43 mL/min; n 5 21 vs 0.51 mL/min;
25th-75th percentile, 0.38-0.64 mL/min; n 5 9;
P 5 .02). This group also included only patients with
salivary gland dysfunction as defined by our flow rate
criterion, whereas all patients without salivary gland
dysfunction had a Greenspan grade #1.
Currently, there is no agreement on how to evaluate
and report MSG involvement based on histopathologi-
cal grading. We propose a composite histopathological
grading score of Greenspan grade and degree of fibrosis
as a tool to evaluate the overall involvement of MSGs.
Greenspan grade reflects the degree of infiltration in
the glands, and fibrosis and atrophy are indicative of
long-term damage. In this subject cohort, atrophy was
highly correlated with fibrosis (r 5 0.96; P\.001) and
thus would not have added information to the overall
score. Mild infiltration and minor degrees of fibrosis
are nonspecific and become more prevalent with aging
[21]. Indeed, in our sample, age was correlated with
degree of the glandular fibrosis (r 5 0.59; P 5 .005).Thus, we propose a cutoff of$3 for the composite score
to indicate likely involvement with cGVHD.
If a composite MSG score of$3 is used as an indi-
cator of salivary gland cGVHD, then 100% of patients
with a salivary flow rate#0.2 mL/min will have histo-
pathological evidence of MSG involvement. However,
60% of patients with histological evidence of MSG
disease in our sample had a normal salivary flow rate.
Factors Associated with Salivary Dysfunction
in cGVHD
To better understand the factors contributing
to salivary dysfunction in cGVHD, we evaluated the
association of various demographic and transplan-
tation-related variables with the presence of salivary
gland dysfunction. In a multivariate model, none of
the demographic and transplant parameters examined,
including age, intensity and type of the conditioning
regimen (myeloablative vs nonmyeloablative, use of
total body irradiation), type of donor (matched related
vs unrelated or haploidentical), severity of oral muco-
sal cGVHD, or time after diagnosis of cGVHD was
predictive of salivary gland dysfunction (data not
shown).
Salivary gland involvement is commonly observed
in patients with scleroderma, and decreased salivary
gland function has been linked to the glandular fibrosis
in these patients [22]. Because sclerodermatous skin
involvement is the hallmark of cGVHD, we hypothe-
sized that skin sclerosis in cGVHD may be associated
with salivary gland involvement. We found no
association between sclerotic skin involvement (super-
ficial or deep) and salivary dysfunction in our cohort
(P5 .81, Fisher’s exact test). There were no differences
in mean salivary flow rate or degree of salivary gland
fibrosis between patients with and without sclerotic
skin involvement (data not shown).
Saliva contains numerous factors important for in-
nate and adaptive mucosal immunity including secre-
tory IgA. Salivary dysfunction might predispose to
oral colonization and subsequent recurrent pulmonary
infections [23]. Furthermore, sicca symptoms have
been reported in association with pulmonary involve-
ment in cGVHD [3]. Using NIH cGVHD lung scores
(a score that ranges from 0 to 3), we observed a trend
toward an association between salivary gland dysfunc-
tion and greater pulmonary cGVHD involvement
(n 5 81; P 5 .015, Cochran-Armitage exact test).
Laboratory Parameters in cGVHDPatients with
Sicca Syndrome
Autoantibodies are commonly associated with and
are used for diagnostic purposes in many autoimmune
conditions. Antibodies to nuclear antigens Ro (SSA)
and La (SSB) are found in a high percentage of patients
with SS [11]. Although we detected a wide range of
Figure 1. (A) Photomicrograph of a salivary gland showing SS-like periductal inflammation, with a periductal infiltrate composed predominantly of
lymphocytes. (Hematoxylin and eosin; original magnification 200.) (B) Severe atrophy with interstitial fibrosis. Most of themucinous acinar parenchyma
has been lost from this lobule, replaced by ductular metaplasia and increased perilobular adipose tissue. There is a mild, predominant lymphocytic
infiltrate in the fibrous interstitium. (Hematoxylin and eosin; original magnification 200.)
Biol Blood Marrow Transplant 16:1362-1369, 2010 1367Salivary Gland Disease in cGVHDautoantibodies in our patient cohort, the individual
prevalence was very low. For example, only 4 patients
had a positive extractable nuclear antigen screen, a test
for all intranuclear antigens used in rheumatology that
includes Ro/SSA and La/SSB (Supplemental Table 2).DISCUSSION
This is the first study to date to comprehensively
analyze clinical and pathological features of sicca syn-
drome in cGVHD using tools that are widely used to
study lacrimal and salivary gland dysfunction in SS.
We found a very high prevalence of sicca complaints
in patients with cGVHD, as well as a significant asso-
ciation between complaints of xerophthalmia and
xerostomia. Salivary and lacrimal glands share a com-
mon developmental origin, and it is possible that
similar or identical antigens in both organs are recog-
nized by alloreactive T cells. However, it also is possi-
ble that our estimate of prevalence exceeds that in the
general cGVHD population because of a referral bias,
because the overwhelming majority of patients in our
study had moderate or severe cGVHD.
In the prospective studies of cGVHD, oral cavity is
the second most commonly involved area [5]. Whether
the symptoms observed result from mucosal (ie, lichen
planus-like) disease or salivary gland involvement is
unclear, however. In fact, in older [7,24] and more
recent [25] studies dealing with the diagnosis and stag-
ing of oral cGVHD, mucosal and MSG biopsy are ad-
vocated as equivalent diagnostic tests. Although
criteria for clinician-assessed lacrimal gland involve-
ment have been defined by the recent NIH consensus
guidelines, salivary and mucosal involvement were
grouped as ‘‘oral’’ involvement [9,10]. But such
a grouping of mucosal and salivary gland involvement
may be counterproductive, because salivary gland
disease and mucosal diseases are managed differently.
For example, whereas topical anti-inflammatory agents
are commonly used for superficial mucosal inflamma-
tion, topical therapy is unlikely to be effective forsalivary gland involvement. Patients with significant
decreases in salivary gland output often benefit from
cholinergic agonists, such as pilocarpine.
Our data provide the first evidence of an important
distinction between salivary and oral mucosal involve-
ment in cGVHD, as demonstrated by the lack of cor-
relation between symptoms and signs related to each
subset. This is demonstrated by the lack of difference
in salivary flow rate between patients with and without
mucosal disease, as well as the lack of correlation be-
tween severity of oral mucosal disease as assessed by
standardized grading and flow rate measurements. In-
deed, patients with mucosal involvement had higher
mean flow rates. The major clinical significance of sal-
ivary gland dysfunction is demonstrated by the greatly
decreased oral cavity-specific quality of life in patients
with xerostomia. In fact, salivary dysfunction had
a much greater impact on oral cavity-specific quality-
of-life score than did mucosal disease. Whereas there
was no significant association between salivary dys-
function and overall HRQL when cGVHD severity
and age were controlled for, the importance of salivary
function for nutritional status is underscored by lower
BMI values and significantly greater reported difficulty
swallowing solid foods in patients with salivary
involvement. Our results suggest that salivary gland
dysfunction might partially explain the observed
association between cGVHD and weight loss [26].
Because no guidelines exist for assessing salivary
gland function in cGVHD, we adapted methods rec-
ommended for evaluating salivary function in SS
[11]. We propose using the SSQ as an initial screening
test of salivary dysfunction, which can be performed at
each visit in the context of screening for cGVHD. In
addition, quantitative evaluation of xerostomia on
a scale of 0-10 should be performed in all patients. In
patients with a positive response to the questionnaire,
the unstimulated salivary flow rate can be measured as
an objective evaluation of salivary gland function. This
test does not involve any special equipment apart from
a preweighed or graduated plastic tube, is reliable, and
can be easily performed by nonspecialists with minimal
1368 Biol Blood Marrow Transplant 16:1362-1369, 2010M. M. Imanguli et al.training. We chose a cutoff of 0.2 cc/min as the lower
limit of normal based on the flow rates in a large cohort
of normal volunteers [20]. Whereas the 0.1 cc/min rec-
ommended by the SS consensus criteria is very specific
for salivary gland involvement by SS, it is not suffi-
ciently sensitive for use in the cGVHD population
and will miss many patients with early disease.
We propose a composite score of mononuclear
infiltration and fibrosis as a histopathological criterion
of MSG involvement with cGVHD. Fibrosis and lym-
phocytic infiltration are included in 2 other scales
developed to evaluate cGVHD in MSGs, but these
scales are limited quantitatively, or the scores are based
on combined mucosal and salivary changes [27-29]. In
our cohort, all patients with a salivary flow rate\0.2
cc/min had positive findings on biopsy (MSG score
$3). Although this finding needs to be validated in
a prospective study, such patients probably do not
need an MSG biopsy to confirm salivary gland
involvement. However, MSG biopsy, as well as
testing of salivary gland functional reserve by
measuring stimulated salivary flow rate, might be
useful in identifying those patients most likely to
benefit from treatment. In our opinion, patients late
in the disease process, as manifested by the extensive
destruction of MSG tissues with fibrosis and atrophy,
are probably unlikely to regain significant function.
Conversely, patients with lymphocytic infiltration
but minimal MSG destruction are probably the most
likely to benefit from immunosuppressive treatment.
The significance of positive histopathology as
a ‘‘gold standard’’ for salivary gland involvement is un-
clear, particularly in asymptomatic patients. Whereas
positive findings are probably sufficient evidence for
the alloreactive response to salivary gland tissue,
whether such involvement would necessarily progress
to symptomatic disease is not known. Similarly, it is
not known whether treatment would reverse the sali-
vary gland pathology, and at what point such treatment
would be most effective. In this sense, using objective
parameters of salivary function could be useful to de-
fine patients who might benefit most from treatment
and who are at greatest risk for xerostomia-related
complications. These hypotheses could be tested in
the future therapeutic trials and natural history studies.
Although the clinical manifestations of lacrimal
and salivary gland injury are similar in chronic
cGVHD and SS, significant differences exist. For
example, the prevalence of autoantibodies in our study
was very low overall, and autoantibodies associated
with the SS (anti-SSA) were detected in only one
patient. Similarly, the pattern of salivary gland histol-
ogy is different in SS, with the much more pronounced
lymphocytic infiltration leads to a higher focus scores
[19]. This could be explained by the different pathoge-
netic mechanisms involved, which merits further study
at the cellular and molecular levels.Sicca syndrome is a common manifestation in
patients with scleroderma, and pathological changes
in the salivary glands have been proposed as part of
the generalized fibrotic process in scleroderma [22].
Because sclerodermatous skin involvement is a com-
mon feature of cGVHD, we evaluated the hypothesis
that these 2 manifestations could be linked. Although
fibrosis is a prominent histopathological feature of
salivary gland disease, we found no association be-
tween skin sclerosis and sicca syndrome, suggesting
that skin and salivary/lacrimal glands are indepen-
dently affected in cGVHD.
Our study found no association between the sali-
vary gland dysfunction in cGVHD and various patient
and transplant characteristics, including age and inten-
sity of the conditioning regimen. Although some previ-
ous studies have linked total body irradiation to
subsequent sicca manifestations [30,31], our study did
not confirm such an association. Indication of more
significantly impaired pulmonary function in patients
with salivary gland dysfunction is intriguing and
merits further study. At least one study reported an
association between sicca syndrome and pulmonary
involvement after allo-HSCT [3]. Unfortunately, how-
ever, no precise definition of sicca syndrome was given,
complicating interpretation of the results.
There are several limitations to this study. Our
cohort included primarily patients with long-standing
and more severe disease, with a mean disease duration
of about 3 years. The data collected provide a cross-
sectional representation of a condition with very
diverse and complex manifestations. The findings pre-
sented may not be directly applicable to routine care of
a general cGVHD patient population. Nevertheless,
we believe that this work lays the foundation for a com-
prehensive assessment of the salivary component of
cGVHD in the research setting. Further refinements
to the proposed guidelines must be made in the context
of prospective studies and controlled clinical trials.
In conclusion, salivary gland involvement by
cGVHD contributes significantly to morbidity and
impaired quality of life in this patient population.
Our results demonstrate the distinction between
salivary and oral mucosal involvement, and we have
proposed specific criteria for assessing salivary gland
involvement in cGVHD. Prospective studies are
needed to validate our findings and address issues of
the optimal timing and nature of therapeutic interven-
tion to prevent and ameliorate the loss of salivary gland
function in cGVHD.ACKNOWLEDGMENTS
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